Zoetis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. 

CEO
Kristin C. Peck
CEOKristin C. Peck
Employees
14,500
Employees14,500
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
1952
Founded1952
Employees
14,500
Employees14,500

ZTS Key Statistics

Market cap
51.65B
Market cap51.65B
Price-Earnings ratio
20.16
Price-Earnings ratio20.16
Dividend yield
1.67%
Dividend yield1.67%
Average volume
3.95M
Average volume3.95M
High today
$122.38
High today$122.38
Low today
$118.33
Low today$118.33
Open price
$119.69
Open price$119.69
Volume
3.52M
Volume3.52M
52 Week high
$177.00
52 Week high$177.00
52 Week low
$115.25
52 Week low$115.25

Stock Snapshot

The current Zoetis(ZTS) stock price is $122.36, with a market capitalization of 51.65B. The stock trades at a price-to-earnings (P/E) ratio of 20.16 and offers a dividend yield of 1.7%.

As of 2026-03-09, Zoetis(ZTS) stock has fluctuated between $118.33 and $122.38. The current price stands at $122.36, placing the stock +3.4% above today's low and -0.0% off the high.

Zoetis(ZTS) shares are trading with a volume of 3.52M, against a daily average of 3.95M.

In the last year, Zoetis(ZTS) shares hit a 52-week high of $177.00 and a 52-week low of $115.25.

In the last year, Zoetis(ZTS) shares hit a 52-week high of $177.00 and a 52-week low of $115.25.

ZTS News

Simply Wall St 2h
Zoetis Faces Pipeline Doubts And Investor Exit Is Its Innovation Story Losing Momentum?

In recent weeks, Zoetis has come under pressure as Nephron Research downgraded the stock to Hold and Jensen Investment Management fully exited its position, bot...

Zoetis Faces Pipeline Doubts And Investor Exit Is Its Innovation Story Losing Momentum?
Simply Wall St 2d
Is Zoetis Now Offering Value After A 1 Year 27% Share Price Slide

If you are wondering whether Zoetis is starting to look like better value after a rough patch, this article walks through what the current share price might be...

Is Zoetis Now Offering Value After A 1 Year 27% Share Price Slide
TipRanks 4d
Zoetis downgraded to Hold from Buy at Nephron Research

Nephron Research analyst Thomas DeBourcy downgraded Zoetis (ZTS) to Hold from Buy with a $131 price target The firm cites a lack of organic growth for the downg...

Analyst ratings

61%

of 23 ratings
Buy
60.9%
Hold
39.1%
Sell
0%

More ZTS News

Nasdaq 4d
Thursday Sector Laggards: Healthcare, Industrial

Looking at the sectors faring worst as of midday Thursday, shares of Healthcare companies are underperforming other sectors, showing a 0.1% loss. Within that gr...

Thursday Sector Laggards: Healthcare, Industrial
Simply Wall St 6d
Zoetis Buys Neogen Genomics To Deepen Precision Livestock Health Story

Zoetis (NYSE:ZTS) has agreed to acquire Neogen Corporation's animal genomics business. The transaction focuses on expanding Zoetis's Precision Animal Health ca...

Zoetis Buys Neogen Genomics To Deepen Precision Livestock Health Story

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.